Sign inCreate account

Report workspace tools

NCT06593457COMPLETEDanonymous

A Phase 1, 2-Part, Placebo-Controlled, Double-Blinded Study to Assess the Effect of Food and Drug-Drug Interaction of Fluconazole on the Pharmacokinetics of NX-5948

Sponsor

Source record

Nurix Therapeutics, Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

IP, Matching Placebo

Indication / condition

AI-normalized

Healthy Volunteers

Intervention

Source record

IP, Matching Placebo

Source & freshness

Source record

NCT ID

NCT06593457

Original source

ClinicalTrials.gov

Source last updated

Mar 14, 2025

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06593457

Title

A Phase 1, 2-Part, Placebo-Controlled, Double-Blinded Study to Assess the Effect of Food and Drug-Drug Interaction of Fluconazole on the Pharmacokinetics of NX-5948

Sponsor

Nurix Therapeutics, Inc.

Status

COMPLETED

Phase

PHASE1

Condition raw

Healthy Volunteers

Condition normalized

Healthy Volunteers

Modality raw

small molecule

Modality normalized

small molecule

Target raw

IP, Matching Placebo

Target normalized

IP, Matching Placebo

Interventions

IP, Matching Placebo

Public preview

Source record

This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, 2-Part, Placebo-Controlled, Double-Blinded Study to Assess the Effect of Food and Drug-Drug Interaction of Fluconazole on the Pharmacokinetics of NX-5948

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06593457

Status

COMPLETED

Phase

PHASE1

Sponsor

Nurix Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 14, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06593457

Indication

Healthy Volunteers

Modality

small molecule

Target

IP, Matching Placebo

Intervention

IP, Matching Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.